ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy

• Published in: Molecules (Basel, Switzerland) Vol. 25; no. 10; p. 2297
• Main Authors: Vitale, Maria Giuseppa, Barbato, Carmela, Crispo, Anna, Habetswallner, Francesco, De Martino, Bernardo Maria, Riccardi, Ferdinando, Maione, Angela, Eisenwagen, Sandra, Vitale, Giovanna, Cartenì, Giacomo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.05.2020; MDPI
• Subjects: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antioxidants; cancer; Cancer therapies; Chemotherapy; chemotherapy-induced peripheral neuropathy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Double-Blind Method; Female; hematological toxicity; Homeostasis; Humans; liver toxicity; Male; Middle Aged; Neuroprotective Agents - administration & dosage; oxaliplatin; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - prevention & control; Peripheral neuropathy; Physiology; PMA-zeolite (clinoptilolite); Zeolites; Zeolites - administration & dosage; PMA-zeolite (clinoptilolite), chemotherapy-induced peripheral neuropathy; oxaliplatin; hematological toxicity; cancer; liver toxicity

Chemotherapy-induced peripheral neuropathy (CIPN) is the most frequently reported adverse effect of oxaliplatin. In this study, we set out to evaluate the role of the panaceo-micro-activation (PMA) zeolite in the reduction of the incidence of CIPN and hematological and liver toxicity. The possible i...